Search by conditions:

 

Protocol Description Phase
17-607 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-456 A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination with Other Agents in Advanced Cancer  (View details on clinicaltrial.gov) Phase I
14-524 A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma  (View details on clinicaltrial.gov) Phase I
16-611 A Phase 1, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
18-228 A Phase 1, Open-Label, Dose-Finding Study of ASN007 in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-288 A Phase 1/1b first-in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with REGN2810 in adult patients with advanced solid tumors  (View details on clinicaltrial.gov) Phase I
16-399 A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase II
18-144 A Phase 2 Study of Dabrafenib and Trametinib in Combination with PDR001 in patients with BRAFV600E metastatic colorectal cancer  (View details on clinicaltrial.gov) Phase II
17-044 A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer  (View details on clinicaltrial.gov) Phase II
17-137 A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer.  (View details on clinicaltrial.gov) Phase I
18-289 A Phase I, First-in-Human, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Daily for 21 Days to Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
18-274 A Phase II Study of M6620 (VX-970) in Selected Solid Tumors  (View details on clinicaltrial.gov) Phase II
17-211 A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)  (View details on clinicaltrial.gov) Phase III
16-193 A pilot study of Ga-68-DOTA-TOC imaging in participants with small bowel carcinoid tumors.  (View details on clinicaltrial.gov) N/A
18-254 An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer (CheckMate 9X8: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 9X8)  (View details on clinicaltrial.gov) Phase III
17-251 An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-615 An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification  (View details on clinicaltrial.gov) Phase II
17-021 Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer  (View details on clinicaltrial.gov) Phase II
17-380 Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-231 Phase Ib/II Study of TAS-102 plus radiation therapy for the treatment of the liver in patients with hepatic metastases from colorectal cancer  (View details on clinicaltrial.gov) Phase II
17-427 Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor CB-1158 as a Single Agent and in Combination with Immune Checkpoint Therapy in Patients with Advanced/Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase I
21 clinical trials listed

Back to Top